Publication date: Oct 10, 2024
In EORTC 18071, the estimated cure rates were 38. 0% (95% CI, 32. 1 to 44. 2) with IPI and 29. 2% (95% CI, 24. 4 to 34. 6) with placebo.
| Concepts | Keywords |
|---|---|
| Checkmate | Checkmate |
| Immunotherapy | Ci |
| Nct00636168 | Cure |
| October | European |
| Higher | |
| Iii | |
| Ipi | |
| Iv | |
| Melanoma | |
| Nivo | |
| Organization | |
| Placebo | |
| Rates | |
| Resected | |
| Stage |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | Cancer |
| drug | DRUGBANK | Nivolumab |
| drug | DRUGBANK | Ipilimumab |
| disease | MESH | recurrence |
Original Article
(Visited 1 times, 1 visits today)